OIC International, Medi Mold, and Fives-AddUp partner to launch 3D printing hub for orthopaedic implants

OIC International (USA), Medi Mold, part of the Andhra Pradesh Medtech Zone (AMTZ) (India), and AddUp, a subsidiary of Fives Group (France) have announced a strategic partnership to establish an advanced orthopaedic implant manufacturing facility powered by 3D printing and precision engineering. The facility will be housed within AMTZ, India’s flagship medical device manufacturing park.

This trilateral arrangement aims to evolve India into a global hub for high-performance orthopaedic implants while aligning with the Indian government’s “Make in India” and medical self-reliance initiatives. OIC is launching a line of implants manufactured in India using advanced additive 3D technology—designed for both domestic and global markets. Developed with proprietary technology, these implants aim to significantly reduce post-surgery recovery time while delivering cutting-edge solutions at a fraction of the cost and can be produced on a mass scale, close to the delivery points.

3D-printing at its core

At the core of the initiative is AddUp’s metal additive manufacturing technology, which will serve as the backbone of the new facility. By enabling the production of geometrically complex, patient-specific implants with reduced material waste, 3D printing introduces a paradigm shift in how orthopaedic devices are designed, validated, and brought to market.

The first metal 3D printer from AddUp’s FormUp range will be installed at AMTZ, enabling rapid prototyping and market entry. This infrastructure, operated by Medi Mold, will aim to ensure speed, flexibility, and efficiency in manufacturing — a vital combination for meeting the growing orthopaedic demand in India and abroad. This entire initiative is well supported by Dr Jitendra Sharma.

Supporting innovation, equity, and market access

Through this partnership, the coalition aims to address three fundamental challenges in orthopaedics: technology-led innovation, affordability and market access. The new facility will offer an integrated manufacturing platform for low-cost implants for public sector procurement, supporting government hospitals and healthcare schemes. Meanwhile, OIC will have the ability to support India’s fast-growing private healthcare market.

Wodehouse Capital also noted significant investor interest in this opportunity, from both financial and strategic players looking to tap into India’s rapidly growing medical devices sector.

This strategic arrangement is expected to be concluded in the next few weeks and subject to necessary approvals.